Stocktoria
Moleculin Biotech, Inc. MBRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-06-02
Moleculin Biotech, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $15.9M | $17.7M | $19.5M | $19.0M | $14.4M |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.6M | -$26.0M | -$29.8M | -$29.0M | -$15.9M |
| Operating cash flow | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M |
| Cash & equivalents | $8.9M | $4.3M | $23.6M | $43.1M | $70.9M |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M |
| Shareholders' equity | $15.0M | $11.2M | $30.9M | $52.2M | $79.0M |
Source: SEC EDGAR filings · CIK 0001659617 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.